Tweeter button Delicious button Digg button Stumbleupon button
Tag Archives: liver diseases
Liver Diseases | Research And Markets: Intercept Pharmaceuticals' Obeticholic Acid For Liver Diseases Report

DUBLIN–(BUSINESS WIRE)– Research and Markets ( ) has announced the addition of the “Intercept Pharmaceuticals’ Obeticholic Acid for Liver Diseases” report to their offering. Obeticholic acid (OCA) is a derivative of chenodeoxycholic acid, the dominant component of bile. It is a potent stimulator of farnesoid X receptor and in that way differs both from chenodeoxycholic acid and ursodeoxycholic    .. more …

Facebook Twitter Email

Liver Diseases | Organisation To Promote Awareness Of Liver Diseases

It seeks to dispel myths misguiding people’s understanding of the risks and impact of liver diseases. A voluntary organisation, CLF has been conducting regular screening camps. Free treatment is provided to those who cannot afford it. CLF also strives to collect a corpus fund to use for the treatment of liver diseases, including surgery for cancers involving the liver and pancreas, according to a    .. more …

Facebook Twitter Email

Liver Diseases | Lumena Pharmaceuticals Raises $45 Million In Series B Financing

SAN DIEGO, March 11, 2014 /PRNewswire/ –Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced that it has secured $45 million in Series B financing. New Enterprise Associates (NEA) led the financing, with Adage Capital Management and RA    .. more …

Facebook Twitter Email

Liver Diseases | Glycerol Phenylbutyrate Reduces Hepatic Encephalopathy Events

PUBLIC RELEASE DATE: 25-Feb-2014 Contact: Dawn Peters sciencenewsroom@wiley.com 781-388-8408 Wiley Glycerol phenylbutyrate reduces hepatic encephalopathy events And ammonia levels compared to placebo Phase 2 trial results published in the March issue of Hepatology , a journal of the American Association for the Study of Liver Diseases, suggests the potential for Glycerol Phenylbutyrate (GPB) to    .. more …

Facebook Twitter Email

Liver Diseases | Milk Thistle Liver Detox – Article Dashboard Directory

The information in this book prepares specialists Natural Standard, based on a thorough systematic review of scientific evidence. The material was examined by the medical faculty of Harvard in the final version was approved by the natural use Standard.HOW cards:The product: The product should be taken orally, as shown. Follow the instructions in the package. If you are not sure that all    .. more …

Facebook Twitter Email

Liver Diseases | Hepatitis A Silent Killer: Experts

Ahmedabad, Dec 2 (IANS) Hepatitis is a “silent killer” and there is a need to draw attention of policy-makers towards increasing incidence of liver diseases, leading experts in hepatitis treatment said here Monday.”Hepatitis is a silent killer and is far more easily transmitted than HIV,” said leading gastroenterologist Sudhanshu Patwari during the launch of the Gujarat chapter of the National    .. more …

Facebook Twitter Email

Liver Diseases | Ocera Therapeutics To Present At BIO Investor On October 8, 2013
liver diseases

SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) — Ocera Therapeutics ( OCRX ), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, will present at the 12th Annual BIO Investor Forum taking place at the Palace Hotel in San Francisco, CA October 8-9, 2013. Ocera’s presentation is    .. more …

Facebook Twitter Email

Liver Diseases | Ocera Announces Post-Merger Closure Of Quebec Research Site
liver diseases

SAN DIEGO, Sept. 17, 2013 (GLOBE NEWSWIRE) — Ocera Therapeutics ( OCRX ), a clinical stage biopharmaceutical company focusing on acute and chronic orphan liver diseases, today announced a restructuring plan involving the closure of operations in its Sherbrooke, Quebec facility effective November 11, 2013. The Sherbrooke facility housed 17 employees and research operations leveraging the Company’s    .. more …

Facebook Twitter Email

Liver Diseases | Jeryl L. Hilleman Joins Ocera Therapeutics As Chief Financial Officer
liver diseases

SAN DIEGO, Sept. 3, 2013 (GLOBE NEWSWIRE) — Ocera Therapeutics ( OCRX ), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Jeryl L. Hilleman has been appointed chief financial officer effective September 3, 2013. Ms. Hilleman will replace Dana McGowan who will continue with the company during a transition period in which the    .. more …

Facebook Twitter Email

Liver Diseases | Ocera Therapeutics Announces Completion Of Merger With Tranzyme
liver diseases

SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) — Ocera Therapeutics, Inc. (“Ocera”), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc. ( TZYM ) (“Tranzyme”) today announced that, following a special meeting of the shareholders of Tranzyme held on July 15, 2013, the Ocera and Tranzyme merger has closed. The combined company is named    .. more …

Facebook Twitter Email

Next Page

Important Disclaimer: Article Comments provided are for general information purposes only and are not intended to substitute for informed professional medical, psychological, tax, accounting, legal, investment, or any other professional advice. We expressly disclaim liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in these comments or anywhere else within the site. Lastly, we do not endorse any article or comment. Use at your own risk.